Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'
By Theresa Schliep · September 28, 2023, 7:38 PM EDT
Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that...
To view the full article, register now.